References
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.27567408
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988. doi:10.1161/01.STR.22.8.9831866765
- Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507. doi:10.1093/europace/euv30926324838
- Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. doi:10.1056/NEJMoa091038321870978
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. doi:10.1056/NEJMoa090556119717844
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. doi:10.1056/NEJMoa131090724251359
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. doi:10.1056/NEJMoa091038321830957
- Degli Esposti L, Sangiorgi D, Di Pasquale G, Gensini GF, Iori I, Buda S, Degli Esposti E; on the behalf of the Study Group. Adherence to treatment and anticoagulation control in vitamin K antagonists-treated patients: an administrative databases analysis in a large Italian population. Farmeconomia. 2011;12(2):53–59.
- Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;i3189. doi:10.1136/bmj.i3189
- Opinion 05/2014 on Privacy and Data Protection. Available from: http://ec.europa.eu/justice/data-protection/article-29/documentation/opinion-recommendation/files/2014/wp216_it.pdf Accessed 927, 2019.
- Cataldo N, Pegoraro V, Ripellino C, et al. Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation. Recenti Prog Med. 2018. doi:10.1701/2865.28904
- Citarella A, Guida A, Capogrosso P, et al. Scelta della terapia antitrombotica in pazienti con fibrillazione atriale non valvolare nella reale pratica clinica. Recenti Prog Med. 2016. doi:10.1701/2260.24336
- Johnson ME, Lefèvre C, Collings S-L, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016;6:e011471. doi:10.1136/bmjopen-2016-011471
- Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5:615–621. doi:10.1161/CIRCOUTCOMES.112.96729922949490
- Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128:1300–1305.e2. doi:10.1016/j.amjmed.2015.05.04426144101
- Giglio AF, Basile E, Santangeli P, Di Biase L, Trotta F, Natale A. Increased risk of myocardial infarction with dabigatran: fact or fiction? J Cardiovasc Med. 2014;15:19–26. doi:10.2459/JCM.0b013e328364beb8
- Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805–810.e2. doi:10.1016/j.ahj.2009.02.00519376304
- Kumar R, Rahman AM, Henry BL. A review of the clinical subgroup analyses from the RE-LY trial. Rev Cardiovasc Med. 2016;17:40–48.27667379
- Lin Y-P, Tan T-Y. Do NOACs improve antithrombotic therapy in secondary stroke prevention in nonvalvular atrial fibrillation? Medicine (Baltimore). 2015;94:e1627. doi:10.1097/MD.000000000000087426402834
- Ten Cate V, Ten Cate H, Verheugt FWA. The global anticoagulant registry in the FIELD-atrial fibrillation (GARFIELD-AF): exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands. Neth Heart J. 2016;24:574–580. doi:10.1007/s12471-016-0874-y27561277
- Huisman MV, Rothman KJ, Paquette M, et al. The changing landscape for stroke prevention in AF. J Am Coll Cardiol. 2017;69:777–785. doi:10.1016/j.jacc.2016.11.02628209218
- Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—european Registry in Atrial Fibrillation (PREFER in AF). EP Eur. 2014;16:6–14.
- Proietti M, Laroche C, Opolski G, et al. ‘Real-world’ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational research programme-atrial fibrillation general registry pilot phase. Europace Euw. 2016;112. doi:10.1093/europace/euw112
- BJCardio Staff. Anticoagulation highlights from the ESC. Br J Cardiol. 2016;23(4).
- Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;j510. doi:10.1136/bmj.j510
- Agenzia Italiana del Farmaco (AIFA). L’uso dei farmaci in Italia—rapporto OsMed 2015. Available from: http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed2015.pdf Accessed 927, 2019.
- Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18:1150–1157. doi:10.1093/europace/euv42126830891
- Agenzia Italiana del Farmaco (AIFA). AIFA Concept paper. I nuovi anticoagulanti orali nella prevenzione di ictus e tromboembolismo sistemico in pazienti con fibrillazione atriale non valvolare. Available from: http://www.agenziafarmaco.gov.it/sites/default/files/version_2012_09_24_cp_noacs_1.pdf Accessed 927, 2019.
- Cangemi DJ, Krill T, Weideman R, Cipher DJ, Spechler SJ, Feagins LA. A comparison of the rate of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants or warfarin. Am J Gastroenterol. 2017;112:734–739. doi:10.1038/ajg.2017.3928244496
- Verdecchia P, Angeli F, Aita A, Bartolini C, Reboldi G. Why switch from warfarin to NOACs? Intern Emerg Med. 2016;11:289–293. doi:10.1007/s11739-016-1411-026972708
- Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. J Med Econ. 2015;18:399–409. doi:10.3111/13696998.2015.100721025586203
- Amin A, Stokes M, Makenbaeva D, Wiederkehr D, Wu N, Lawrence JH. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. J Med Econ. 2014;17:771–781. doi:10.3111/13696998.2014.95368225133458
- Urooj F, Kulkarni A, Stapleton D, Kaluski E. New oral anticoagulants in nonvalvular atrial fibrillation: new oral anticoagulants in non-valvular atrial fibrillation. Clin Cardiol. 2016;39:739–746. doi:10.1002/clc.2016.39.issue-1227716952
- Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15:776–785. doi:10.3111/13696998.2012.68055522449118